Pathological variants in genes encoding calmodulin are associated with severe clinical presentations, including recurrent ventricular fibrillation and sudden death. Beta-receptor antagonists (beta-blockers) and sodium-channel antagonists have been reported as pharmacotherapies in these disorders; however, recent data have demonstrated the importance of derangements in calcium channel inactivation. We report a sustained attempt to use calcium-channel antagonists to treat calmodulinopathy and review the treatment strategies reported in the literature to date.
http://ift.tt/2vHJzRj
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου